Arbutus Biopharma
ABUS
ABUS
51 hedge funds and large institutions have $47.6M invested in Arbutus Biopharma in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
6% more funds holding
Funds holding: 48 → 51 (+3)
0.25% less ownership
Funds ownership: 38.13% → 37.88% (-0.25%)
Holders
51
Holding in Top 10
1
Calls
$1.21M
Puts
$5K
Top Buyers
| 1 | +$2.38M | |
| 2 | +$1.3M | |
| 3 | +$509K | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$372K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$318K |
Top Sellers
| 1 | -$2.05M | |
| 2 | -$1.14M | |
| 3 | -$580K | |
| 4 |
Goldman Sachs
New York
|
-$499K |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$273K |